<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Human ehrlichiosis and anaplasmosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Human ehrlichiosis and anaplasmosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Human ehrlichiosis and anaplasmosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Micah T McClain, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel J Sexton, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first case of human ehrlichiosis was described in 1986 when a patient became ill with fever, hypotension, confusion, acute renal failure, coagulopathy, and gastrointestinal hemorrhage [
         <a href="#rid1">
          1
         </a>
         ]. The etiologic agent was identified as
         <em>
          Ehrlichia chaffeensis
         </em>
         , the agent of human monocytic ehrlichiosis (HME). In 1994,
         <em>
          Anaplasma phagocytophilum
         </em>
         was identified as the agent of human granulocytic anaplasmosis (HGA) [
         <a href="#rid2">
          2
         </a>
         ]. HGA was previously called human granulocytic ehrlichiosis (HGE). These tickborne illnesses are recognized as separate disease entities even though their clinical and laboratory manifestations are similar.
        </p>
        <p>
         The epidemiology, clinical manifestations, diagnosis, and treatment of human ehrlichiosis and anaplasmosis will be reviewed here. An in-depth overview of the microbiology of ehrlichial organisms and the mechanisms by which they cause disease are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7903.html" rel="external">
          "Biology of Anaplasmataceae"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ehrlichiae are obligate intracellular bacteria that grow within membrane-bound vacuoles in human and animal leukocytes (
         <a class="graphic graphic_picture graphicRef60471" href="/z/d/graphic/60471.html" rel="external">
          picture 1
         </a>
         ). The two most important species to infect humans include
         <em>
          E. chaffeensis
         </em>
         , the causative agent of human monocytic ehrlichiosis (HME), and
         <em>
          A. phagocytophilum
         </em>
         , the agent of human granulocytic anaplasmosis (HGA). Less commonly, ehrlichiosis is caused by
         <em>
          Ehrlichia ewingii
         </em>
         , which was discovered in 1999 [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Human monocytic ehrlichiosis'
         </a>
         below and
         <a class="local">
          'Human granulocytic anaplasmosis'
         </a>
         below and
         <a class="local">
          'E. ewingii infection'
         </a>
         below.)
        </p>
        <p>
         In 2009, a third species of
         <em>
          Ehrlichia
         </em>
         was identified in four patients from Wisconsin and Minnesota who had fever, malaise, headache, and lymphopenia [
         <a href="#rid4">
          4
         </a>
         ]; more than 100 cases have been subsequently reported [
         <a href="#rid5">
          5
         </a>
         ]. Molecular methods, culture techniques, and serologic testing demonstrated that this species is closely related to
         <em>
          Ehrlichia muris
         </em>
         , which is found in Eastern Europe and Asia. In 2007, this organism was named
         <em>
          E. muris
         </em>
         <em>
          eauclairensis
         </em>
         [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Another species less commonly seen is
         <em>
          Neorickettsia sennetsu
         </em>
         , which causes a mild mononucleosis-like illness. Neorickettsial illness has not been reported outside the Far East and Southeast Asia [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         A more detailed discussion of the taxonomy, phylogeny, and host specificity of these bacteria is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7903.html" rel="external">
          "Biology of Anaplasmataceae"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of human monocytic ehrlichiosis (HME) and human granulocytic anaplasmosis (HGA) occur in the spring and summer months, and many of the epidemiologic features are similar (
         <a class="graphic graphic_table graphicRef64475" href="/z/d/graphic/64475.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef50677" href="/z/d/graphic/50677.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Human monocytic ehrlichiosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Human monocytic ehrlichiosis (HME) is endemic in the southeastern, south-central, and mid-Atlantic regions of the United States (
         <a class="graphic graphic_figure graphicRef118614" href="/z/d/graphic/118614.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ]. A few cases of HME have been recognized in New England and the Pacific Northwest, and isolated cases have been reported in Europe, Africa, and Mexico [
         <a href="#rid9">
          9
         </a>
         ]. Serologic studies have suggested that
         <em>
          E. chaffeensis
         </em>
         also occurs in Mexico, Venezuela, Brazil, Chile, Korea, and China. Serologic and molecular testing of vertebrates and humans have also detected
         <em>
          E. chaffeensis
         </em>
         or a closely related ehrlichial agent in Venezuela, Croatia, Poland, Greece, Italy, and several countries in central Africa [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
         The total number of cases of HME reported annually to the United States Centers for Disease Control and Prevention (CDC) quadrupled from 2000 to 2008 and has continued to increase [
         <a href="#rid5">
          5,12
         </a>
         ]. From 2008 to 2012, the incidence of HME was 3.2 cases per million person-years, with wide variations in incidence by state [
         <a href="#rid13">
          13
         </a>
         ]. However, these numbers likely underestimate the actual incidence of the disease, as many cases are not confirmed by laboratory testing and current surveillance systems rely on voluntary reporting by clinicians. Depending on geographic location and exposure history, incidence rates as high as 660 per 100,000 have been reported in outbreak situations, and serologic surveys have shown evidence of asymptomatic infection [
         <a href="#rid14">
          14,15
         </a>
         ]. Tick bites, exposure to wildlife, and golfing have been associated with an increased risk of infection.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Human granulocytic anaplasmosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The human granulocytic anaplasmosis (HGA) agents
         <em>
          Ehrlichia phagocytophila
         </em>
         and
         <em>
          Ehrlichia equi
         </em>
         are now recognized as the same organism, which has been renamed
         <em>
          A. phagocytophilum
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/7903.html" rel="external">
          "Biology of Anaplasmataceae"
         </a>
         .)
        </p>
        <p>
         HGA is more frequently reported than HME in the United States, with an average reported annual incidence of 6.3 cases per million population from 2008 to 2012 [
         <a href="#rid16">
          16
         </a>
         ]. In the United States, regional estimates of HGA vary significantly by locale, and most reported cases of anaplasmosis are from Vermont, Maine, Rhode Island, Minnesota, Massachusetts, Wisconsin, New Hampshire, and New York (
         <a class="graphic graphic_figure graphicRef72124" href="/z/d/graphic/72124.html" rel="external">
          figure 2
         </a>
         ). The number of cases of HGA reported to the CDC increased more than 12-fold from 2001 to 2011 [
         <a href="#rid17">
          17
         </a>
         ] and continued to rise, reaching 5762 cases reported in the United States during 2017 [
         <a href="#rid18">
          18
         </a>
         ]. These numbers are likely incomplete, as reporting is a passive process and a significant number of cases diagnosed on clinical grounds are not confirmed serologically. In addition, serologic studies of persons with a history of tick bites suggest that many infections are asymptomatic [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Infection with HGA is also recognized in Europe and Asia with similar risk factors of tick bite exposure [
         <a href="#rid20">
          20-23
         </a>
         ]. The majority of human cases in Europe have been reported from Central Europe (eg, Slovenia) and Scandinavia (eg, Sweden) [
         <a href="#rid24">
          24
         </a>
         ]. Although numerous studies done in various European countries have shown that
         <em>
          A. phagocytophilum
         </em>
         is commonly present in rodents, small mammals, and ticks, relatively few human cases of HGA have been recognized, and the course of disease when infection does occur appears to be less severe than that seen in the United States [
         <a href="#rid25">
          25
         </a>
         ]. It is currently unknown if these findings are due to the presence of less pathogenic or nonpathogenic variants of
         <em>
          A. phagocytophilum
         </em>
         in Europe [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          E. ewingii infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 1999,
         <em>
          E. ewingii
         </em>
         , the agent of canine granulocytic ehrlichiosis, was found to cause disease in humans. Several of these cases occurred in Missouri, an area endemic for
         <em>
          E. chaffeensis
         </em>
         , and the clinical features of illness in these patients were initially confused with those of HME [
         <a href="#rid3">
          3
         </a>
         ]. Subsequently, however, sequencing of isolates distinguished the organism in these cases from
         <em>
          E. chaffeensis
         </em>
         .
        </p>
        <p>
         From 2008 to 2012, 55 cases of
         <em>
          E. ewingii
         </em>
         infection were reported, with an incidence ratio of 0.04 cases per million person-years [
         <a href="#rid13">
          13
         </a>
         ]. Human
         <em>
          E. ewingii
         </em>
         infection is likely to be widely distributed throughout the south-central and southeastern United States as the vector for this disease (
         <em>
          Amblyomma americanum
         </em>
         , the "lone star" tick) is found throughout this wide geographic area. Most human
         <em>
          E. ewingii
         </em>
         infections have been recognized in immunocompromised patients [
         <a href="#rid26">
          26
         </a>
         ]. It is likely that some cases of
         <em>
          E. ewingii
         </em>
         infection are misdiagnosed as HME since the most commonly used serologic tests for convalescent antibodies to
         <em>
          Ehrlichia
         </em>
         do not distinguish between
         <em>
          E. ewingii
         </em>
         and
         <em>
          E. chaffeensis
         </em>
         infection [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2780515656">
         <span class="h2">
          E. muris eauclairensis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          E. muris eauclairensis
         </em>
         infection is uncommon and has only been described in patients from Minnesota and Wisconsin. It is transmitted by
         <em>
          Ixodes scapularis
         </em>
         , the same tick that transmits
         <em>
          A. phagocytophilum
         </em>
         , Lyme disease, babesiosis, and Powassan virus. Its principal host is
         <em>
          Peromyscus leucopus
         </em>
         , the white-footed mouse [
         <a href="#rid5">
          5
         </a>
         ]. The clinical features of this illness resemble
         <em>
          E. chaffeensis
         </em>
         infection (see
         <a class="local">
          'Clinical manifestations'
         </a>
         below). In a series of 69 patients, 27 percent had immunocompromising conditions [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3212671696">
         <span class="h1">
          TRANSMISSION
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Tick vectors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The distribution of vector tick species dictates the epidemiology of human monocytic ehrlichiosis (HME), human granulocytic anaplasmosis (HGA), and other tickborne illnesses, and is partially overlapping in the United States (
         <a class="graphic graphic_figure graphicRef56962" href="/z/d/graphic/56962.html" rel="external">
          figure 3
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HME
         </strong>
         – The principal vector of
         <em>
          E. chaffeensis
         </em>
         (agent of human monocytic ehrlichiosis [HME]) is the lone star tick (
         <em>
          Amblyomma americanum
         </em>
         ) (
         <a class="graphic graphic_picture graphicRef71086" href="/z/d/graphic/71086.html" rel="external">
          picture 2
         </a>
         ). Other ticks such as
         <em>
          Amblyomma maculatum
         </em>
         ,
         <em>
          Dermacentor variabilis
         </em>
         , and
         <em>
          Ixodes pacificus
         </em>
         have occasionally been found to contain
         <em>
          E. chaffeensis
         </em>
         DNA, but their role in transmission is either minor or unlikely.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Surveys of
         <em>
          A. americanum
         </em>
         ticks have shown rates of infection ranging from 0 to 27 percent; these wide ranges have been noted not only from different geographic locations, but also from the same location sampled at different times [
         <a href="#rid11">
          11
         </a>
         ]. The tick vectors of
         <em>
          E. chaffeensis
         </em>
         in South America, Asia, and Africa have not been firmly identified [
         <a href="#rid11">
          11
         </a>
         ]. Epidemiologic studies suggest that the tick vector for the novel species
         <em>
          E. muris
         </em>
         <em>
          eauclairensis
         </em>
         , identified in Wisconsin and Minnesota in 2009, is
         <em>
          I. scapularis
         </em>
         [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HGA
         </strong>
         – In the northeastern and midwestern regions of the United States,
         <em>
          A. phagocytophilum
         </em>
         (agent of human granulocytic anaplasmosis [HGA]) is transmitted by
         <em>
          I. scapularis
         </em>
         (
         <a class="graphic graphic_picture graphicRef73802" href="/z/d/graphic/73802.html" rel="external">
          picture 3
         </a>
         ), the tick that is also the vector of
         <em>
          E. muris eauclairensis,
         </em>
         Lyme disease, babesiosis, and Powassan virus [
         <a href="#rid28">
          28
         </a>
         ] (see
         <a class="local">
          'Coinfection with other tickborne illnesses'
         </a>
         below).
         <em>
          I. pacificus
         </em>
         (
         <a class="graphic graphic_picture graphicRef60501" href="/z/d/graphic/60501.html" rel="external">
          picture 4
         </a>
         ), the western black-legged tick, is the primary vector of HGA in the western United States, and
         <em>
          Ixodes ricinus
         </em>
         is the primary vector in much of Europe [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Animal reservoirs
         </span>
         <span class="headingEndMark">
          —
         </span>
         White-tail deer are the principal animal reservoir for
         <em>
          E. chaffeensis
         </em>
         , and deer and the white-footed mouse are the principal animal hosts for
         <em>
          A. phagocytophilum
         </em>
         [
         <a href="#rid29">
          29
         </a>
         ]. Although
         <em>
          E. chaffeensis
         </em>
         infection has been noted in coyotes and goats, their role in the epidemiology of HME remains to be determined [
         <a href="#rid11">
          11,30-32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Other modes of transmission
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although HME and HGA are primarily tickborne diseases,
         <em>
          Ehrlichia
         </em>
         and
         <em>
          Anaplasma
         </em>
         transmission have been reported to occur through transfusion of blood, leuko-reduced red cells, and platelets [
         <a href="#rid33">
          33-37
         </a>
         ].
         <em>
          E. chaffeensis
         </em>
         has also been reported after solid organ transplantation, although most of these cases were probably acquired post-transplant from tick bites rather than donor-derived [
         <a href="#rid38">
          38-40
         </a>
         ]. Transmission by other means has also been suggested, such as maternal-child transmission [
         <a href="#rid41">
          41
         </a>
         ] and transmission through direct contact with slaughtered deer [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both human monocytic ehrlichiosis (HME) and human granulocytic anaplasmosis (HGA) typically present as an acute illness; however, there is a wide spectrum of disease ranging from subclinical and self-limited to subacute and prolonged. While many clinical manifestations overlap, HME infections are more likely to be severe and require hospitalization compared with HGA [
         <a href="#rid13">
          13,16
         </a>
         ]. Most published data relate to infection in adults.
        </p>
        <p>
         Ehrlichial diseases generally have an incubation period of one to two weeks, but a shorter period may be seen. In a study of 18 adults with HGA, for example, symptoms appeared an average of 5.5 days after a tick bite was noted [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         For those who develop symptoms, the clinical manifestations of HGA and HME can vary from mild to severe.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most patients are febrile, but clinically mild or inapparent infection probably occurs. In studies of transfusion-related disease, the donors implicated as the source of transmission were asymptomatic [
         <a href="#rid34">
          34-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonspecific symptoms such as malaise, myalgia, headache, and chills occur in over two-thirds of cases, while nausea, vomiting, arthralgias, and cough occur in 25 to 50 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older patients and those with comorbid illnesses or immunosuppressive conditions such as HIV appear to have more severe infections [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="local">
          'Immunocompromised hosts'
         </a>
         below and
         <a class="local">
          'Morbidity and mortality'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rash, which can be macular, maculopapular, or rarely petechial, occurs in a minority of patients [
         <a href="#rid44">
          44
         </a>
         ]. In one review, rash was noted in 36 percent of 211 cases of HME [
         <a href="#rid45">
          45
         </a>
         ]. Rash is rarer in HGA infection, occurring in only 1 of 41 patients in one report [
         <a href="#rid46">
          46
         </a>
         ]. Some experts caution that when rash is present, alternative etiologies of rash should be considered. For example, the presence of classic erythema migrans rash should raise the possibility of infection or coinfection with
         <em>
          Borrelia burgdorferi.
         </em>
         Similarly, diffuse maculopapular, petechial, or vasculitic rash is more typical of Rocky Mountain spotted fever (RMSF) or other illnesses [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7913.html" rel="external">
          "Clinical manifestations of Lyme disease in adults", section on 'Erythema migrans'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7913.html" rel="external">
          "Clinical manifestations of Lyme disease in adults", section on 'Cutaneous findings'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7904.html" rel="external">
          "Clinical manifestations and diagnosis of Rocky Mountain spotted fever", section on 'Rash'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic symptoms, including mental status changes, stiff neck, clonus, and meningoencephalitis, can be present in up to 20 percent of ehrlichiosis cases but are not as commonly reported in anaplasmosis. In a retrospective review of 57 individuals with confirmed
         <em>
          Ehrlichia
         </em>
         , 15 (26 percent) had neurologic findings that prompted cerebrospinal fluid (CSF) analysis. Eight of the samples were abnormal, and the most common abnormalities were lymphocytic pleocytosis and elevated protein levels [
         <a href="#rid47">
          47
         </a>
         ]. In a separate case report of ehrlichial meningitis, characteristic inclusions compatible with
         <em>
          Ehrlichia
         </em>
         morulae were seen within mononuclear cells in the CSF [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some patients present subacutely with unexplained fever, and fever can persist for up to two months in the absence of therapy [
         <a href="#rid44">
          44,49
         </a>
         ]. In one study, 6 of 41 cases of HME recognized at a medical center in Missouri during a four-year span had protracted fever ranging in duration from 17 to 51 days [
         <a href="#rid49">
          49
         </a>
         ]. Another report described an untreated patient with HGA in whom
         <em>
          A. phagocytophilum
         </em>
         DNA was detected 21 days after the onset of symptoms despite the presence of high antibody titers [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A case of rapidly progressive myocarditis due to
         <em>
          E. chaffeensis
         </em>
         infection, leading to the death of a previously healthy 15-year-old girl, has been reported [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         More detailed discussions of the complications that can result from HME and HGA infection are found below. (See
         <a class="local">
          'Complications'
         </a>
         below and
         <a class="local">
          'Morbidity and mortality'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data in children with ehrlichiosis have largely consisted of case reports and small series. A report from the Tick-Borne Infections in Children Study Group evaluated 32 children with HME in the "tick belt" of the southeastern United States [
         <a href="#rid52">
          52
         </a>
         ]. The major disease manifestations were fever in all patients; headache, myalgia, and rash (66 to 69 percent); and nausea/vomiting, altered mental status, and lymphadenopathy (47 to 56 percent). The triad of fever, headache, and rash was present in 48 percent. These findings are similar to those in adults. In this report, a minority of the children had severe disease. Seven (22 percent) were admitted to the intensive care unit, four of whom required ventilatory and hemodynamic support.
        </p>
        <p>
         Anaplasmosis is rarely reported in children. In one small series of nine patients, children with HGA frequently presented with fever, headache, and malaise; children appeared to be more likely than adults to complain of abdominal pain [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H640621886">
         <span class="h2">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data are limited on the effect of HME and HGA in pregnancy. In one case series of six pregnant women with HGA, all had mild disease [
         <a href="#rid54">
          54
         </a>
         ]. However, another report described a pregnant woman with HGA who spontaneously aborted her child while being treated for HGA [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Perinatal transmission of HGA has been described in case reports [
         <a href="#rid41">
          41,54,56
         </a>
         ]. Performing polymerase chain reaction (PCR) on blood from the neonate should be considered if HGA or HME is diagnosed in the mother during pregnancy. (See
         <a class="local">
          'Polymerase chain reaction'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Immunocompromised hosts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe disease has been reported in patients with factors leading to impaired immunity, such as advanced age, immunosuppression, chronic illness, and malignancy [
         <a href="#rid19">
          19,57,58
         </a>
         ]. (See
         <a class="local">
          'Morbidity and mortality'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of laboratory abnormalities occur in HME and HGA infections. The most common, occurring in 50 to 90 percent of patients, are leukopenia (often accompanied by a left shift), thrombocytopenia, and elevated plasma levels of aminotransferases (transaminases), lactate dehydrogenase, and alkaline phosphatase [
         <a href="#rid46">
          46,52,59
         </a>
         ]. Nonhemolytic anemia and an elevated plasma creatinine also may be seen. Lab findings consistent with hemolytic anemia should prompt consideration of
         <em>
          Babesia
         </em>
         infection or coinfection in the appropriate epidemiologic setting. (See
         <a class="medical medical_review" href="/z/d/html/5670.html" rel="external">
          "Babesiosis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Leukopenia in patients with HGA can be caused by lymphopenia or neutropenia. Lymphopenia tends to occur in the early stages of infection, followed by lymphocytosis with atypical lymphocytes [
         <a href="#rid43">
          43
         </a>
         ]. In contrast, the initial neutrophil count in patients with HGA is inversely related to the duration of symptoms before treatment is begun. In one study, for example, neutropenia was seen in three of four patients who had HGA for more than four days versus only one of nine patients with a shorter duration of illness [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Thrombocytopenia was observed more often than leukopenia in a retrospective study of 144 patients with HGA [
         <a href="#rid60">
          60
         </a>
         ]. This study also included matched controls with other acute febrile illnesses, and the risk of having ehrlichiosis in this group of patients varied inversely with granulocyte and platelet counts. The number of band neutrophils was also increased in most patients with HGA from the time of onset through the eighth day of illness. The authors emphasized that automated differential counting of leukocytes may not separate band neutrophils from segmented neutrophils or detect morulae, and they stressed the important point that a manual differential count should be ordered if ehrlichiosis is suspected.
        </p>
        <p>
         Changes in the CSF can be seen in patients in whom a lumbar puncture is performed because of neurologic symptoms. In one report, for example, lymphocytic pleocytosis and elevated CSF protein levels were found in 21 of 38 patients with
         <em>
          E. chaffeensis
         </em>
         infection [
         <a href="#rid47">
          47
         </a>
         ]. In contrast, patients with HGA who have neurologic symptoms typically have relatively normal CSF [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The complications of HME and HGA infections include seizures, coma, and renal and respiratory failure. Cardiac complications can also occur, including heart failure in previously healthy patients, (with or without electrocardiographic or chemical evidence of myocarditis) [
         <a href="#rid61">
          61
         </a>
         ], and pericardial effusions leading to tamponade [
         <a href="#rid62">
          62
         </a>
         ]. In addition, a septic or toxic shock-like illness may occur in patients with severe HME or HGA infections [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Other complications include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary infections
         </strong>
         – HGA infection can be complicated by serious and even fatal opportunistic infections, including herpes simplex esophagitis, invasive aspergillosis, and candidiasis [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemophagocytic lymphohistiocytosis
         </strong>
         – While rare, there have also been an increasing number of reports of patients with HME or HGA infections who developed hemophagocytic lymphohistiocytosis (HLH) [
         <a href="#rid40">
          40,65
         </a>
         ]. HLH can be fulminant and difficult to treat. Underlying HME or HGA should be treated if it is suspected to have triggered HLH [
         <a href="#rid66">
          66-68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">
          "Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Post-infectious complications
         </strong>
         – Demyelinating polyneuropathy and brachial plexopathy have been temporally linked with HGA infections [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1074317192">
         <span class="h2">
          Coinfection with other tickborne illnesses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because individual ticks can carry multiple different pathogens, humans can simultaneously acquire more than one infection after a single tick bite.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coinfections with HGA
         </strong>
         – In addition to
         <em>
          A. phagocytophilum,
         </em>
         the
         <em>
          I. scapularis
         </em>
         tick is also the vector for
         <em>
          B. burgdorferi
         </em>
         (the agent of Lyme disease) and
         <em>
          Babesia
         </em>
         , and humans have become simultaneously infected with a combination of these organisms after a single tick bite. In studies of
         <em>
          I. scapularis
         </em>
         ticks from different locales, 2 to 26 percent of ticks were coinfected with
         <em>
          B. burgdorferi
         </em>
         and
         <em>
          A. phagocytophilum
         </em>
         [
         <a href="#rid28">
          28,71
         </a>
         ]; in Connecticut and Wisconsin, concurrent HGA and Lyme disease may occur in as many as 3 to 15 percent of patients with tickborne infection [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical features that should raise suspicion for possible concomitant Lyme disease include erythema migrans rash, neurologic symptoms (such as Bell palsy), and cardiac rhythm abnormalities. Hemolytic anemia or intraerythrocytic parasitic inclusions on peripheral blood smear should raise suspicion for
         <em>
          Babesia
         </em>
         coinfection. (See
         <a class="medical medical_review" href="/z/d/html/7913.html" rel="external">
          "Clinical manifestations of Lyme disease in adults", section on 'Early disseminated disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5670.html" rel="external">
          "Babesiosis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other pathogens that can be carried by
         <em>
          I. scapularis
         </em>
         include
         <em>
          E. muris eauclairensis
         </em>
         ,
         <em>
         </em>
         other
         <em>
          Borrelia
         </em>
         species (eg,
         <em>
          B. miyamotoi
         </em>
         ), and Powassan virus. These are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/101368.html" rel="external">
          "Borrelia miyamotoi infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1293.html" rel="external">
          "Arthropod-borne encephalitides", section on 'Powassan virus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coinfections with HME
         </strong>
         – Patients with HME do not typically have concurrent tickborne infections, although simultaneous bites from ticks of multiple species may lead to coinfection [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1617481538">
         <span class="h2">
          Morbidity and mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Overall, more than 50 percent of reported cases require hospitalization [
         <a href="#rid13">
          13,74
         </a>
         ]. However, case fatality rates for both HME and HGA have declined as reported cases have increased over the past decade. Estimated mortality rates range from 1.0 to 2.7 percent for HME and are around 0.3 percent for HGA [
         <a href="#rid13">
          13,16,59,75
         </a>
         ]. Secondary opportunistic infections (likely due to leukopenia) such as fungal pneumonia are common in patients who die [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Ehrlichiosis may be particularly life-threatening in immunocompromised patients. In a review of 21 patients with HIV coinfection, 6 of 13 died and several other patients had severe illnesses including respiratory failure, gastrointestinal hemorrhage, and fungal superinfections [
         <a href="#rid44">
          44
         </a>
         ]. Severe disease, including hemophagocytic lymphohistiocytosis, can occur in solid organ transplant recipients [
         <a href="#rid39">
          39,40,76,77
         </a>
         ]. One report of 23 cases of HME in this population found that organ failure occurred in all patients, and six patients (25 percent) died [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Outcome data are more limited in children. In a review of 32 children with HME, there were no deaths, but three had significant neurologic deficits at discharge [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="local">
          'Children'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H4202946012">
         <span class="h2">
          Clinical suspicion
         </span>
         <span class="headingEndMark">
          —
         </span>
         A presumptive diagnosis of human monocytic ehrlichiosis (HME) and human granulocytic anaplasmosis (HGA) can be made in patients who have a compatible systemic febrile illness with appropriate epidemiologic exposures and no clear alternative explanation. As an example, outdoor exposure in an endemic area during spring or summer months coupled with a febrile illness and isolated leukopenia and/or thrombocytopenia provides strong circumstantial evidence for the diagnosis of ehrlichiosis. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
         The diagnosis should be considered even in those with a history of HGA or HME since prior infection may not confer long-lasting immunity. One patient experienced two episodes of HGA spaced two years apart [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         Given the potential for rapid progression to serious illness, we agree with the Centers for Disease Control and Prevention (CDC) guidance that antimicrobial treatment should be administered as soon as infection is clinically suspected [
         <a href="#rid79">
          79
         </a>
         ]. Delaying treatment can lead to increased morbidity and mortality. (See
         <a class="local">
          'General principles'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H237453990">
         <span class="h2">
          Confirming the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         As stated above, we suggest treating for HME or HGA as soon as the diagnosis is suspected. The results of testing should not delay treatment.
        </p>
        <p class="headingAnchor" id="H3625943195">
         <span class="h3">
          Approach to testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         When HME or HGA is suspected, we send blood samples for HME or HGA polymerase chain reaction (PCR), HME or HGA serology, and a blood smear. In areas endemic for both HME and HGA, separate PCR and serologic tests should be sent for each organism.
        </p>
        <p>
         PCR is widely used and is able to provide diagnostic results during the acute setting. Importantly, a positive PCR result confirms infection, but a negative result does not definitively rule out disease. (See
         <a class="local">
          'Polymerase chain reaction'
         </a>
         below.)
        </p>
        <p>
         Serology can also provide a definitive diagnosis, but its clinical utility in the acute setting is limited. If PCR is negative and suspicion for HME or HGA remains, we submit a second serologic test two to four weeks later to make a diagnosis; a fourfold rise in the antibody titers between the acute and convalescent tests can confirm the diagnosis. Accuracy and interpretation of these microbiologic tests are described further below. (See
         <a class="local">
          'Serology'
         </a>
         below.)
        </p>
        <p>
         Microscopic examination of a blood smear can sometimes provide rapid confirmation of the diagnosis. Although sensitivity for this test is lower than that of PCR, it is highly specific and can provide the most rapid results. Obtaining a smear of the buffy coat in blood can improve sensitivity, but buffy coat examination is labor intensive for the laboratory and is not frequently performed. (See
         <a class="local">
          'Blood smears'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1553961265">
         <span class="h3">
          Polymerase chain reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polymerase chain reaction (PCR)-based testing can detect HME and HGA infections early in the course of illness. Tests are widely available from multiple commercial labs, as well as the CDC and some state public health laboratories.
        </p>
        <p>
         PCR assays for HME and HGA have excellent sensitivity and specificity during the first week of illness [
         <a href="#rid79">
          79
         </a>
         ]. Sensitivity and specificity vary from laboratory to laboratory, but have been reported to be as high as 95 to 100 percent [
         <a href="#rid80">
          80-83
         </a>
         ].
        </p>
        <p>
         However, the PCR test may be negative despite infection, particularly in specific situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PCR tests sent more than one week after onset of symptoms are less reliable [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Because PCR assays detect single species, a PCR test for
         <em>
          A. phagocytophilum
         </em>
         does not detect
         <em>
          Ehrlichia
         </em>
         species, and vice versa. Furthermore, a PCR test for
         <em>
          E. chaffeensis
         </em>
         may not detect
         <em>
          E. ewingii, E. muris eauclairensis,
         </em>
         or other
         <em>
          Ehrlichia
         </em>
         spp [
         <a href="#rid4">
          4
         </a>
         ]. If multiple species are suspected, individual tests for each suspected organism should be ordered. Many laboratories provide PCR panels that can detect multiple organisms simultaneously.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Samples obtained from patients on antibiotic therapy may have false-negative PCR results [
         <a href="#rid84">
          84
         </a>
         ]. Some data suggest that PCR sensitivity falls within 48 hours of administration of appropriate antibiotics [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1824860231">
         <span class="h3">
          Serology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serologic tests measure specific immunoglobulin (Ig)M and IgG antibody levels against HME and HGA.
        </p>
        <p>
         To diagnose HME or HGA by serologic testing, one blood sample should be obtained upon presentation (ie, an acute sample) and a second sample should be obtained two to four weeks after the first antibody test is sent (ie, a convalescent sample). We agree with CDC guidance that a definitive diagnosis requires at least a fourfold change in the IgG titer between the acute and convalescent stage [
         <a href="#rid85">
          85
         </a>
         ]. To confirm an infection, most labs require at least one of the IgG titers to be at least 1:64 to 1:80 [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
         Serologic tests are available from multiple commercial laboratories and most state public health laboratories. Laboratories use different methodologies to perform serologic tests, but IgG indirect fluorescent antibody assays (IFA) are the historical reference standard for HME or HGA.
        </p>
        <p>
         Paired serologic tests for IgG have been estimated to be 80 to 86 percent sensitive if ordered and interpreted correctly [
         <a href="#rid87">
          87,88
         </a>
         ].
        </p>
        <p>
         Like PCR tests, serologic tests can be negative despite active infection, particularly in specific situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early in the clinical course, serologic tests are often negative because antibodies often do not reach detectable levels within the first week of illness. Patients with negative initial serology can be confirmed to have disease if a subsequent convalescent sample shows a significant conversion from undetectable to a positive titer, as described above.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tests for the wrong organism can cause negative results because serologic tests that detect
         <em>
          E. chaffeensis
         </em>
         (the cause of HME) do not reliably detect HGA, and vice versa. Therefore, in areas endemic for both HME and HGA, a serologic test should be sent for each organism. In contrast, most serologic tests for
         <em>
          E. chaffeensis
         </em>
         do detect multiple
         <em>
          Ehrlichia
         </em>
         species due to cross-reactivity [
         <a href="#rid12">
          12,59,86,89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antibiotic treatment can abort IgM and IgG production, which may prevent fourfold rises in convalescent titers [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Unlike PCR, serologic tests can be positive in the absence of ongoing infection, particularly in specific situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with past HME or HGA infections can have persistently positive IgG results, often past one year [
         <a href="#rid46">
          46,90
         </a>
         ]. As described above, correct timing of acute and convalescent titers can differentiate past from acute infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Single positive IgG antibody titers should not be used to make a definitive diagnosis of acute or recent infection, regardless of whether the sample was drawn in the acute phase or the convalescent phase. As an example, in a case report of an individual with two HGA infections two years apart, the IgG titer at the time of reinfection was the same as that measured 13 months after the first infection (1:80); the diagnosis was definitively made by a significant rise in the convalescent titer [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Like IgG, single positive IgM antibody titers should not be used to make a definitive diagnosis of acute or recent infection. IgM antibody tests are frequently offered by commercial labs, but they are significantly less specific than IgG titers and thus do not necessarily indicate acute or past infection [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Blood smears
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with HME or HGA, intracytoplasmic inclusions called morulae can sometimes be seen on a blood smear. When seen in the right clinical setting, they definitively confirm the diagnosis. If available at an institution, performing a buffy coat examination of a blood smear from centrifuged blood can increase the likelihood of finding morulae.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with HGA, morulae are detected in the neutrophils (
         <a class="graphic graphic_picture graphicRef60471" href="/z/d/graphic/60471.html" rel="external">
          picture 1
         </a>
         ). Reported frequency varies between 20 and 80 percent. One report found obvious morulae in the peripheral smear in 28 of 35 (80 percent) patients with laboratory-confirmed HGA infection [
         <a href="#rid46">
          46
         </a>
         ]. Another study of 141 patients with HGA from the upper Midwest and New York found that 86 (61 percent) had morulae visualized in neutrophils [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In individuals with HME, morulae are detected in the mononuclear cells. They are identified less commonly, in approximately 1 to 20 percent of patients (
         <a class="graphic graphic_figure graphicRef138647" href="/z/d/graphic/138647.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid84">
          84,86,91,92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H871735059">
         <span class="h3">
          Other diagnostic tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other diagnostic tests are rarely used.
        </p>
        <p>
         A few cases of HME have been diagnosed by immunohistochemical staining of bone marrow tissue or autopsy tissue from spleen, lymph nodes, liver, or lung for ehrlichial antigens [
         <a href="#rid93">
          93-95
         </a>
         ].
        </p>
        <p>
         Routine blood cultures cannot detect the organisms. Culturing the organisms is extremely difficult, so culture has no meaningful role in the diagnosis of HME or HGA. Until 1995, only two isolates of
         <em>
          E. chaffeensis
         </em>
         had been recovered from humans; in both cases, the process required over 30 days of cultivation [
         <a href="#rid59">
          59
         </a>
         ]. The isolation of
         <em>
          A. phagocytophilum
         </em>
         from three patients has also been accomplished using a cell culture system derived from human promyelocytic leukemia cells [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7903.html" rel="external">
          "Biology of Anaplasmataceae"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H598069412">
         <span class="h2">
          Evaluation for coinfections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with suspected HGA should be evaluated for other infections that are transmitted by the same
         <em>
          I. scapularis
         </em>
         tick (eg, Lyme, babesiosis), if suspected (see
         <a class="local">
          'Coinfection with other tickborne illnesses'
         </a>
         above). This is especially important for babesiosis because standard treatment for HGA (
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ) would not be effective for babesiosis. Diagnostic testing for Lyme and babesiosis is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7914.html" rel="external">
          "Diagnosis of Lyme disease", section on 'Approach to diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5670.html" rel="external">
          "Babesiosis: Clinical manifestations and diagnosis", section on 'Clinical approach'
         </a>
         .)
        </p>
        <p>
         Patients with HME typically do not have coinfections.
        </p>
        <p class="headingAnchor" id="H3094803897">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis for human monocytic ehrlichiosis (HME) and human granulocytic anaplasmosis (HGA) is broad and includes both infectious and noninfectious etiologies. In addition, coinfection with other tickborne infections should be considered. The clinical presentation can help to narrow the differential diagnosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Individuals with severe sepsis or septic shock
         </strong>
         – Severe sepsis and septic shock from other bacterial infections can mimic severe HME and HGA infections. Examples include bacteremia, acute cholangitis, community-acquired pneumonia, urosepsis, and meningoencephalitis. For these patients, broad-spectrum antimicrobial therapy, including treatment for HME or HGA, should be started until a definitive microbiologic diagnosis is made. (See
         <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">
          "Evaluation and management of suspected sepsis and septic shock in adults", section on 'Empiric antibiotic therapy (first hour)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Individuals with fever plus leukopenia, thrombocytopenia, and/or abnormal aminotransferases
         </strong>
         – Infections with lab findings that mimic HME and HGA include mononucleosis-like illnesses caused by Epstein-Barr virus, cytomegalovirus, and acute HIV. Other viruses can cause similar syndromes, including viral hepatitides like hepatitis A, B, and C.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other arthropod infections should also be considered. Rocky Mountain spotted fever (RMSF) has a similar clinical presentation to HME and HGA except RMSF is much more likely to have an associated rash. Babesiosis can have similar symptoms and lab findings as HME and HGA, except patients with babesiosis also have evidence of hemolytic anemia or intracytoplasmic parasitic inclusions on blood smears; the presence of
         <em>
          Babesia
         </em>
         infection does not rule out coinfection with
         <em>
          Anaplasma
         </em>
         ,
         <em>
         </em>
         as discussed above. (See
         <a class="local">
          'Coinfection with other tickborne illnesses'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Noninfectious illnesses can present with fever and lab findings consistent with HME and HGA. Such conditions include thrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome (HUS), hemophagocytic lymphohistiocytosis (HLH), and hematologic malignancy. Drug reactions can also mimic these findings, including reactions to
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         and chemotherapeutic agents.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H882068943">
         <span class="h2">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment should be initiated in all symptomatic patients suspected of having ehrlichiosis or anaplasmosis. Human ehrlichiosis can be a serious disease with significant morbidity, particularly if appropriate antibiotics are delayed. (See
         <a class="local">
          'Morbidity and mortality'
         </a>
         above.)
        </p>
        <p>
         For patients who present with severe sepsis or septic shock, broad-spectrum antibiotic therapy is also typically used until the diagnosis of human monocytic ehrlichiosis (HME) or human granulocytic anaplasmosis (HGA) is confirmed. (See
         <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">
          "Evaluation and management of suspected sepsis and septic shock in adults", section on 'Initial resuscitative therapy'
         </a>
         .)
        </p>
        <p>
         Some patients have subclinical or undiagnosed illness, and make a full recovery without treatment. There is no evidence that untreated ehrlichiosis produces longer-term symptoms such as those reported after some cases of Lyme disease.
        </p>
        <p class="headingAnchor" id="H2608840972">
         <span class="h2">
          Treatment regimens
         </span>
        </p>
        <p class="headingAnchor" id="H137005294">
         <span class="h3">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         There have been no controlled trials examining the efficacy of antimicrobial therapy in either HME or HGA. Treatment recommendations are based on clinical case series and in vitro data.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The drug of choice for all patients is
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         . This is also the preferred therapy for many other tickborne infections (eg, Rocky Mountain spotted fever [RMSF]) that can be confused with HGA and HME. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seven to 10 days of therapy is commonly recommended, and relapses have not been described with this treatment duration [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Special considerations for pregnant women and those with concurrent tickborne infections are discussed below. (See
         <a class="local">
          'Pregnancy'
         </a>
         below and
         <a class="local">
          'Patients with concurrent tickborne infection (coinfection)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Although most experience is with tetracyclines, if an alternative agent is used, we generally prefer
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         due to reports of successful outcomes using this agent [
         <a href="#rid19">
          19,33,96-98
         </a>
         ]. However, there is a general lack of consensus on this issue given a paucity of data for second-line agents.
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          Chloramphenicol
         </a>
         also appears to be effective, but it can be associated with significant hematologic toxicity and is not available in most pharmacies in the United States. A more detailed discussion of chloramphenicol is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7912.html" rel="external">
          "Treatment of Rocky Mountain spotted fever", section on 'Chloramphenicol'
         </a>
         .)
        </p>
        <p>
         The benefit of tetracyclines was illustrated in a study of 237 patients with HME, in which 3 of 49 outpatients (6.1 percent) treated only with
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         required hospitalization, compared with 35 of 38 patients (92 percent) who were treated with antibiotics other than tetracycline or
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. Among hospitalized patients, recovery was faster for those initially treated with tetracycline (median 16 days) or chloramphenicol (median 12 days) than for those initially treated with other antibiotics (median 27 days); furthermore, severe illness or death was more probable in patients who did not receive tetracycline or chloramphenicol until eight days or more after the onset of symptoms (odds ratio 4.38; 95% CI 1.36-14.0). The benefit of early therapy was supported in a subsequent study, in which delayed therapy was associated with an increased rate of transfer to the intensive care unit, mechanical ventilation, longer hospital stay, and a longer length of illness [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         Similar results are seen in patients with HGA. In one study, for example, 2 of 12 patients died; the other 10 improved rapidly after the administration of
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         , with defervescence occurring within 48 hours after initiation of treatment [
         <a href="#rid100">
          100
         </a>
         ]. In another report, all 18 patients with HGA who were treated with doxycycline had resolution of fever within 48 hours of starting therapy. The four patients with
         <em>
          E. ewingii
         </em>
         also responded to treatment with doxycycline, including three receiving immunosuppressive therapy for other conditions [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         There is only a limited amount of retrospectively collected clinical data on the comparative efficacy of tetracyclines (most commonly
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ) and
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         in the treatment of HME. In one study of hospitalized patients with this disorder, those treated with doxycycline defervesced one day sooner than those treated with chloramphenicol (two versus three days) [
         <a href="#rid44">
          44
         </a>
         ]. This study and in vitro data have led some experts to recommend doxycycline as the treatment of choice even in children [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         While there are no documented cases of
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         resistance in these diseases, some patients have a prolonged course and do not respond well to therapy. In a case report, persistent infection with
         <em>
          E. chaffeensis
         </em>
         was documented in a man who died 68 days after initial hospitalization for his acute illness [
         <a href="#rid101">
          101
         </a>
         ]. Despite treatment with tetracycline and
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         ,
         <em>
          E. chaffeensis
         </em>
         morulae were found in samples of his bone marrow on day 18 and at post-mortem. Most reported cases of prolonged illness involved patients with varying degrees of immunosuppression, who may be at higher risk for severe outcomes. (See
         <a class="local">
          'Morbidity and mortality'
         </a>
         above.)
        </p>
        <p>
         In one in vitro study,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         (minimum inhibitory concentration [MIC] ranging from 0.06 to 0.5 mcg/mL) was active against eight strains of
         <em>
          A. phagocytophilum
         </em>
         isolated from various geographic areas of the United States [
         <a href="#rid96">
          96
         </a>
         ]. However, there is limited clinical experience with this agent, and relapse of infection has been described in at least one patient with HGA infection treated with levofloxacin [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H227339490">
         <span class="h3">
          Adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          Doxycycline
         </a>
         can be given either orally or intravenously at a dose of 100 mg twice daily. We agree with published recommendations that doxycycline be continued for 10 days or for three to five days after defervescence, whichever is longer [
         <a href="#rid31">
          31,57
         </a>
         ]. Special considerations in pregnant women are discussed below. (See
         <a class="local">
          'Pregnancy'
         </a>
         below.)
        </p>
        <p>
         Patients who have intolerance or allergy to tetracyclines can be treated with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         (300 mg twice daily) for 7 to 10 days, but careful follow-up and monitoring of such patients is recommended, as there are only a few case reports on the efficacy of this agent [
         <a href="#rid19">
          19,33,96-98
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children should be treated with
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         (4.4 mg/kg per day, divided every 12 hours, intravenously or orally; maximum 100 mg/dose) [
         <a href="#rid103">
          103
         </a>
         ]. Treatment should continue for at least three days after defervescence. In general, the duration of treatment is 7 to 14 days.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          Doxycycline
         </a>
         can be used regardless of age. Although some tetracyclines can cause dental staining in children &lt;8 years of age, the risk of such staining with doxycycline is minimal if a short course of therapy is administered. The American Academy of Pediatrics supports use of doxycycline for ≤21 days in children of all ages [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         therapy (10 mg/kg twice per day, maximum 300 mg per dose) for 7 to 10 days can be given as an alternative to
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         for treatment of ehrlichiosis and anaplasmosis, but children treated with this agent should be carefully monitored to ensure clinical resolution of disease [
         <a href="#rid57">
          57
         </a>
         ]. Successful treatment of HGA with rifampin has been reported in two children, but clinical experience is limited [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1024828901">
         <span class="h2">
          Special considerations
         </span>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h3">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         At present, no guidelines exist for the treatment of HME or HGA in pregnancy. We suggest
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         rather than an alternative antibiotic, since there is most experience with this agent. In addition, case reports support that doxycycline can been used successfully and safely in pregnant women with HME or HGA [
         <a href="#rid54">
          54,106
         </a>
         ].
        </p>
        <p>
         Although older tetracyclines are relatively contraindicated in pregnancy because of the risk of hepatotoxicity in the mother [
         <a href="#rid86">
          86
         </a>
         ] and adverse effects on fetal bone and teeth [
         <a href="#rid107">
          107,108
         </a>
         ], these events are extremely rare with
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         . Observational studies support the relative safety of doxycycline compared with older tetracyclines in both pregnancy and in children [
         <a href="#rid109">
          109,110
         </a>
         ]. As an example, in a systematic review, there was no correlation between the use of doxycycline during pregnancy and teratogenic effects or dental staining in children [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
         An alternative to
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         in pregnant women is
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         . Rifampin is both active and bactericidal against HGA in vitro [
         <a href="#rid96">
          96,111
         </a>
         ] and has been effective in small numbers of pregnant women with HGA [
         <a href="#rid33">
          33,54,97
         </a>
         ].
        </p>
        <p>
         The risk of perinatal transmission is discussed above. (See
         <a class="local">
          'Pregnant women'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3359770060">
         <span class="h3">
          Patients with concurrent tickborne infection (coinfection)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients infected with HGA who are suspected to have potential coinfection with other tickborne pathogens such as
         <em>
          B. burgdorferi
         </em>
         ,
         <em>
          B. miyamotoi
         </em>
         , and
         <em>
          Babesia microti
         </em>
         should receive empiric treatment for all suspected infections until a definitive microbiologic diagnosis is made. Clinical findings that suggest coinfection are described above. (See
         <a class="local">
          'Coinfection with other tickborne illnesses'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Borrelia burgdorferi
          </em>
         </strong>
         <strong>
          and other
         </strong>
         <strong>
          <em>
           Borrelia
          </em>
         </strong>
         <strong>
          species
         </strong>
         <em>
         </em>
         –
         <em>
         </em>
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          Doxycycline
         </a>
         regimens of at least 10 days will treat coinfection with
         <em>
          B. burgdorferi
         </em>
         (ie, Lyme disease) if it is early in its course (as is the case with coinfection), as well as
         <em>
          B. miyamotoi
         </em>
         . By contrast,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         is not effective against
         <em>
          Borrelia
         </em>
         spp, so another antibiotic should be added to rifampin when
         <em>
          Borrelia
         </em>
         coinfection is suspected. (See
         <a class="medical medical_review" href="/z/d/html/7896.html" rel="external">
          "Treatment of Lyme disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101368.html" rel="external">
          "Borrelia miyamotoi infection", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Babesia microti
          </em>
         </strong>
         –
         <em>
         </em>
         None of the agents used to treat anaplasmosis are effective for
         <em>
          Babesia
         </em>
         , so a specific regimen is needed if concurrent babesiosis is suspected or diagnosed. (See
         <a class="medical medical_review" href="/z/d/html/113483.html" rel="external">
          "Babesiosis: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best way to prevent infection with
         <em>
          A. phagocytophilum
         </em>
         and
         <em>
          E. chaffeensis
         </em>
         is through the use of tick repellants, such as DEET (N,N-diethyl-3-methylbenzamide, previously called N,N-diethyl-m-toluamide) or
         <a class="drug drug_general" data-topicid="9759" href="/z/d/drug information/9759.html" rel="external">
          permethrin
         </a>
         , and prompt examination for and removal of ticks. Other strategies include bathing after outdoor activities in areas where ticks are abundant, placing clothes in dryers for a short time after outdoor activities, wearing protective white clothing, and simply avoiding areas where ticks are abundant. Tick control in domestic animals (eg, dogs, cats) may also be helpful [
         <a href="#rid112">
          112,113
         </a>
         ].
        </p>
        <p>
         Antibiotic therapy with
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         after a tick bite is
         <strong>
          not
         </strong>
         recommended to prevent ehrlichiosis and anaplasmosis, despite the fact that 5 to 15 percent of lone star ticks may be infected with
         <em>
          E. chaffeensis
         </em>
         and 10 to 50 percent of
         <em>
          I. scapularis
         </em>
         ticks may be infected with
         <em>
          A. phagocytophilum
         </em>
         in endemic areas [
         <a href="#rid86">
          86
         </a>
         ]. Instead, patients with tick bites should be told to report any symptoms compatible with infection in the two weeks following a bite. The use of antibiotics to prevent Lyme disease is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7916.html" rel="external">
          "Evaluation of a tick bite for possible Lyme disease", section on 'Antimicrobial prophylaxis'
         </a>
         .)
        </p>
        <p>
         There are no licensed vaccines for ehrlichiosis or anaplasmosis. Animal studies suggest that it may take 24 hours following tick attachment to transmit
         <em>
          A. phagocytophilum
         </em>
         infection [
         <a href="#rid114">
          114
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">
          "Prevention of arthropod and insect bites: Repellents and other measures"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2519258338">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111579.html" rel="external">
          "Society guideline links: Tick-borne infections (Lyme disease, ehrlichiosis, anaplasmosis, babesiosis, and Rocky Mountain spotted fever)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         –
         <strong>
         </strong>
         Although similar in clinical presentation, diagnosis, and treatment, human monocytic ehrlichiosis (HME) and human granulocytic anaplasmosis (HGA) are caused by different organisms. HME is caused by
         <em>
          Ehrlichia
         </em>
         species, most commonly
         <em>
          E. chaffeensis
         </em>
         . HGA is caused by
         <em>
          Anaplasma phagocytophilum.
         </em>
         (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         –
         <strong>
         </strong>
         HME is transmitted by the lone star tick (
         <em>
          Amblyomma americanum
         </em>
         ) and is endemic in the southeastern, south-central, and mid-Atlantic United States. HGA is transmitted by the
         <em>
          Ixodes scapularis
         </em>
         tick and is endemic in Minnesota, Wisconsin, and the northeastern region of the United States. Cases have also been reported from other parts of the world. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         –
         <strong>
         </strong>
         HME and HGA have similar clinical manifestations, ranging from mild illness to septic shock. Severe disease is more common with HME infection and in immunocompromised individuals. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Onset of illness is usually within one to two weeks of the tick bite.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Typical symptoms include fever, malaise, myalgia, and headache.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Typical laboratory findings include leukopenia, thrombocytopenia, and transaminitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         –
         <strong>
         </strong>
         In endemic areas, a presumptive clinical diagnosis of HME or HGA can be made in patients who present with a typical febrile illness and outdoor exposure. As soon as either is suspected, we send blood samples for polymerase chain reaction (PCR) testing, a blood smear, and serology for the suspected species. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A positive PCR test strongly supports the diagnosis of HME or HGA, but a negative result does not rule out disease, particularly after the first week of illness.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A single positive serologic test does not confirm the diagnosis of HME or HGA. If HME or HGA infection is suspected despite a negative PCR, we send a second convalescent serologic test two to four weeks later. A fourfold difference between acute and convalescent IgG titers is confirmatory. IgM titers have questionable utility in the diagnosis of HME or HGA.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If seen on blood smear in the right clinical setting, intracytoplasmic inclusions called morulae (
         <a class="graphic graphic_picture graphicRef60471" href="/z/d/graphic/60471.html" rel="external">
          picture 1
         </a>
         ) definitively confirm the diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         –
         <strong>
         </strong>
         As soon as HME or HGA is suspected, empiric treatment should be initiated. For patients with severe sepsis or septic shock, broad-spectrum antimicrobials should be added until the diagnosis of HME or HGA is confirmed. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For treatment of HME or HGA in nonpregnant adults and children, we recommend
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         rather than a nontetracycline agent (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Although some tetracyclines can cause dental staining in children &lt;8 years of age, the risk of such staining with doxycycline is minimal if a short course of therapy is administered.
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         is an alternative for individuals who cannot take doxycycline (eg, severe allergy). (See
         <a class="local">
          'Adults'
         </a>
         above and
         <a class="local">
          'Children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For treatment of HME or HGA in pregnant individuals, we also suggest
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         rather than
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Although most tetracyclines are contraindicated in pregnancy because of the risk of hepatotoxicity in the mother and adverse effects on fetal bone and teeth, these are extremely rare with doxycycline. (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment should be continued for at least three days after defervescence. In adults, the minimum duration is 10 days. For children, there is no minimum duration, but most patients require 7 to 14 days of treatment. (See
         <a class="local">
          'Adults'
         </a>
         above and
         <a class="local">
          'Children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with HGA in whom coinfection is suspected, 10 days of
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         is sufficient to treat most cases of early Lyme disease or infection with
         <em>
          B. miyamotoi
         </em>
         . An additional regimen is needed for babesiosis coinfection. (See
         <a class="local">
          'Patients with concurrent tickborne infection (coinfection)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         –
         <strong>
         </strong>
         Preventive measures include the use of tick repellants and prompt examination and removal of ticks after exposure to tick-infested environments. (See
         <a class="local">
          'Prevention'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7895.html" rel="external">
          "Prevention of Lyme disease"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Maeda K, Markowitz N, Hawley RC, et al. Human infection with Ehrlichia canis, a leukocytic rickettsia. N Engl J Med 1987; 316:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen SM, Dumler JS, Bakken JS, Walker DH. Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. J Clin Microbiol 1994; 32:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buller RS, Arens M, Hmiel SP, et al. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. N Engl J Med 1999; 341:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritt BS, Sloan LM, Johnson DK, et al. Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. N Engl J Med 2011; 365:422.
          </a>
         </li>
         <li class="breakAll">
          United States Centers for Disease Control and Prevention. Ehrlichiosis: Epidemiology and Statistics. https://www.cdc.gov/ehrlichiosis/stats/index.html. (Accessed on July 10, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritt BS, Allerdice MEJ, Sloan LM, et al. Proposal to reclassify Ehrlichia muris as Ehrlichia muris subsp. muris subsp. nov. and description of Ehrlichia muris subsp. eauclairensis subsp. nov., a newly recognized tick-borne pathogen of humans. Int J Syst Evol Microbiol 2017; 67:2121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumler JS, Barbet AF, Bekker CP, et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol 2001; 51:2145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases--United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 59:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gongóra-Biachi RA, Zavala-Velázquez J, Castro-Sansores CJ, González-Martínez P. First case of human ehrlichiosis in Mexico. Emerg Infect Dis 1999; 5:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez MC, Gutiérrez CN, Monger F, et al. Ehrlichia chaffeensis in child, Venezuela. Emerg Infect Dis 2008; 14:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yabsley MJ. Natural history of Ehrlichia chaffeensis: vertebrate hosts and tick vectors from the United States and evidence for endemic transmission in other countries. Vet Parasitol 2010; 167:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Anaplasmosis and ehrlichiosis - Maine, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols Heitman K, Dahlgren FS, Drexler NA, et al. Increasing Incidence of Ehrlichiosis in the United States: A Summary of National Surveillance of Ehrlichia chaffeensis and Ehrlichia ewingii Infections in the United States, 2008-2012. Am J Trop Med Hyg 2016; 94:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Standaert SM, Dawson JE, Schaffner W, et al. Ehrlichiosis in a golf-oriented retirement community. N Engl J Med 1995; 333:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egizi A, Fefferman NH, Jordan RA. Relative Risk for Ehrlichiosis and Lyme Disease in an Area Where Vectors for Both Are Sympatric, New Jersey, USA. Emerg Infect Dis 2017; 23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahlgren FS, Heitman KN, Drexler NA, et al. Human granulocytic anaplasmosis in the United States from 2008 to 2012: a summary of national surveillance data. Am J Trop Med Hyg 2015; 93:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakken JS, Dumler JS. Human granulocytic anaplasmosis. Infect Dis Clin North Am 2015; 29:341.
          </a>
         </li>
         <li class="breakAll">
          The Centers for Disease Control and Prevention. Anaplasmosis statistics and epidemiology. http://www.cdc.gov/anaplasmosis/stats/index.html (Accessed on July 10, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakken JS, Dumler JS. Human granulocytic ehrlichiosis. Clin Infect Dis 2000; 31:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumler JS, Choi KS, Garcia-Garcia JC, et al. Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerg Infect Dis 2005; 11:1828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doudier B, Olano J, Parola P, Brouqui P. Factors contributing to emergence of Ehrlichia and Anaplasma spp. as human pathogens. Vet Parasitol 2010; 167:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santino I, Cammarata E, Franco S, et al. Multicentric study of seroprevalence of Borrelia burgdorferi and Anaplasma phagocytophila in high-risk groups in regions of central and southern Italy. Int J Immunopathol Pharmacol 2004; 17:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SH, Park S, Lee YS, et al. Diagnosis and molecular characteristics of human infections caused by Anaplasma phagocytophilum in South Korea. J Microbiol 2018; 56:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strle F. Human granulocytic ehrlichiosis in Europe. Int J Med Microbiol 2004; 293 Suppl 37:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanco JR, Oteo JA. Human granulocytic ehrlichiosis in Europe. Clin Microbiol Infect 2002; 8:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paddock CD, Folk SM, Shore GM, et al. Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with human immunodeficiency virus. Clin Infect Dis 2001; 33:1586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson DK, Schiffman EK, Davis JP, et al. Human Infection with Ehrlichia muris-like Pathogen, United States, 2007-2013(1). Emerg Infect Dis 2015; 21:1794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadelman RB, Horowitz HW, Hsieh TC, et al. Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis. N Engl J Med 1997; 337:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockhart JM, Davidson WR, Stallknecht DE, et al. Isolation of Ehrlichia chaffeensis from wild white-tailed deer (Odocoileus virginianus) confirms their role as natural reservoir hosts. J Clin Microbiol 1997; 35:1681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kocan AA, Levesque GC, Whitworth LC, et al. Naturally occurring Ehrlichia chaffeensis infection in coyotes from Oklahoma. Emerg Infect Dis 2000; 6:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parola P, Raoult D. Ticks and tickborne bacterial diseases in humans: an emerging infectious threat. Clin Infect Dis 2001; 32:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dugan VG, Little SE, Stallknecht DE, Beall AD. Natural infection of domestic goats with Ehrlichia chaffeensis. J Clin Microbiol 2000; 38:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakken JS, Dumler S. Human granulocytic anaplasmosis. Infect Dis Clin North Am 2008; 22:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annen K, Friedman K, Eshoa C, et al. Two cases of transfusion-transmitted Anaplasma phagocytophilum. Am J Clin Pathol 2012; 137:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alhumaidan H, Westley B, Esteva C, et al. Transfusion-transmitted anaplasmosis from leukoreduced red blood cells. Transfusion 2013; 53:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regan J, Matthias J, Green-Murphy A, et al. A confirmed Ehrlichia ewingii infection likely acquired through platelet transfusion. Clin Infect Dis 2013; 56:e105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goel R, Westblade LF, Kessler DA, et al. Death from Transfusion-Transmitted Anaplasmosis, New York, USA, 2017. Emerg Infect Dis 2018; 24:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sachdev SH, Joshi V, Cox ER, et al. Severe life-threatening Ehrlichia chaffeensis infections transmitted through solid organ transplantation. Transpl Infect Dis 2014; 16:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mowla SJ, Drexler NA, Cherry CC, et al. Ehrlichiosis and Anaplasmosis among Transfusion and Transplant Recipients in the United States. Emerg Infect Dis 2021; 27:2768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha A, Browning C, Dandamudi R, et al. Donor-derived Ehrlichiosis: 2 Clusters Following Solid Organ Transplantation. Clin Infect Dis 2022; 74:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz HW, Kilchevsky E, Haber S, et al. Perinatal transmission of the agent of human granulocytic ehrlichiosis. N Engl J Med 1998; 339:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakken JS, Krueth JK, Lund T, et al. Exposure to deer blood may be a cause of human granulocytic ehrlichiosis. Clin Infect Dis 1996; 23:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguero-Rosenfeld ME, Horowitz HW, Wormser GP, et al. Human granulocytic ehrlichiosis: a case series from a medical center in New York State. Ann Intern Med 1996; 125:904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everett ED, Evans KA, Henry RB, McDonald G. Human ehrlichiosis in adults after tick exposure. Diagnosis using polymerase chain reaction. Ann Intern Med 1994; 120:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishbein DB, Dawson JE, Robinson LE. Human ehrlichiosis in the United States, 1985 to 1990. Ann Intern Med 1994; 120:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakken JS, Krueth J, Wilson-Nordskog C, et al. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996; 275:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratnasamy N, Everett ED, Roland WE, et al. Central nervous system manifestations of human ehrlichiosis. Clin Infect Dis 1996; 23:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry DS, Miller RS, Hooke JA, et al. Ehrlichial meningitis with cerebrospinal fluid morulae. Pediatr Infect Dis J 1999; 18:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roland WE, McDonald G, Caldwell CW, Everett ED. Ehrlichiosis--a cause of prolonged fever. Clin Infect Dis 1995; 20:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumler JS, Bakken JS. Human granulocytic ehrlichiosis in Wisconsin and Minnesota: a frequent infection with the potential for persistence. J Infect Dis 1996; 173:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Havens NS, Kinnear BR, Mató S. Fatal ehrlichial myocarditis in a healthy adolescent: a case report and review of the literature. Clin Infect Dis 2012; 54:e113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schutze GE, Buckingham SC, Marshall GS, et al. Human monocytic ehrlichiosis in children. Pediatr Infect Dis J 2007; 26:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sigurjonsdottir VK, Feder HM Jr, Wormser GP. Anaplasmosis in pediatric patients: Case report and review. Diagn Microbiol Infect Dis 2017; 89:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhand A, Nadelman RB, Aguero-Rosenfeld M, et al. Human granulocytic anaplasmosis during pregnancy: case series and literature review. Clin Infect Dis 2007; 45:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muffly T, McCormick TC, Cook C, Wall J. Human granulocytic ehrlichiosis complicating early pregnancy. Infect Dis Obstet Gynecol 2008; 2008:359172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casau NC, Hewins ME, Zaleznik DF. Treatment of human granulocytic ehrlichiosis during pregnancy and risk of perinatal transmission. Scand J Infect Dis 2002; 34:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis 2021; 72:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esbenshade A, Esbenshade J, Domm J, et al. Severe ehrlichia infection in pediatric oncology and stem cell transplant patients. Pediatr Blood Cancer 2010; 54:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumler JS, Bakken JS. Ehrlichial diseases of humans: emerging tick-borne infections. Clin Infect Dis 1995; 20:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. Clin Infect Dis 2001; 32:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanek NN, Kazi S, Cepero NM, et al. Human ehrlichiosis causing left ventricular dilatation and dysfunction. Clin Infect Dis 1996; 22:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodman JL, Nelson C, Vitale B, et al. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. N Engl J Med 1996; 334:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Liu Y, Ni D, et al. Nosocomial transmission of human granulocytic anaplasmosis in China. JAMA 2008; 300:2263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumler JS. Anaplasma and Ehrlichia infection. Ann N Y Acad Sci 2005; 1063:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson TM, Brown MS, Rabbat M, Slim J. Hemophagocytic Lymphohistiocytosis Associated with Anaplasmosis. J Glob Infect Dis 2017; 9:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otrock ZK, Gonzalez MD, Eby CS. Ehrlichia-Induced Hemophagocytic Lymphohistiocytosis: A Case Series and Review of Literature. Blood Cells Mol Dis 2015; 55:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabler SS, Hogan PG, Fritz SA, et al. Incidence and treatment of hemophagocytic lymphohistiocytosis in hospitalized children with Ehrlichia infection. Pediatr Blood Cancer 2020; 67:e28436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otrock ZK, Eby CS, Burnham CD. Human ehrlichiosis at a tertiary-care academic medical center: Clinical associations and outcomes of transplant patients and patients with hemophagocytic lymphohistiocytosis. Blood Cells Mol Dis 2019; 77:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakken JS, Erlemeyer SA, Kanoff RJ, et al. Demyelinating polyneuropathy associated with human granulocytic ehrlichiosis. Clin Infect Dis 1998; 27:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz HW, Marks SJ, Weintraub M, Dumler JS. Brachial plexopathy associated with human granulocytic ehrlichiosis. Neurology 1996; 46:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz I, Fish D, Daniels TJ. Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease. N Engl J Med 1997; 337:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belongia EA. Epidemiology and impact of coinfections acquired from Ixodes ticks. Vector Borne Zoonotic Dis 2002; 2:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sexton DJ, Corey GR, Carpenter C, et al. Dual infection with Ehrlichia chaffeensis and a spotted fever group rickettsia: a case report. Emerg Infect Dis 1998; 4:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuriakose K, Pettit AC, Schmitz J, et al. Assessment of Risk Factors and Outcomes of Severe Ehrlichiosis Infection. JAMA Netw Open 2020; 3:e2025577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon DM, Branda JA, Clark SH, et al. Ehrlichiosis and anaplasmosis subcommittee report to the Tick-borne Disease Working Group. Ticks Tick Borne Dis 2021; 12:101823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safdar N, Love RB, Maki DG. Severe Ehrlichia chaffeensis infection in a lung transplant recipient: a review of ehrlichiosis in the immunocompromised patient. Emerg Infect Dis 2002; 8:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan HP, Dumler JS, Maley WR, et al. Human monocytic ehrlichiosis: an emerging pathogen in transplantation. Transplantation 2001; 71:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz HW, Aguero-Rosenfeld M, Dumler JS, et al. Reinfection with the agent of human granulocytic ehrlichiosis. Ann Intern Med 1998; 129:461.
          </a>
         </li>
         <li class="breakAll">
          Ehrlichiosis. Clinical &amp; Laboratory Diagnosis. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/ehrlichiosis/healthcare-providers/diagnosis.html. (Accessed on December 10, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell CA, Patel R. A real-time combined polymerase chain reaction assay for the rapid detection and differentiation of Anaplasma phagocytophilum, Ehrlichia chaffeensis, and Ehrlichia ewingii. Diagn Microbiol Infect Dis 2005; 53:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reller ME, Dumler JS. Development and Clinical Validation of a Multiplex Real-Time Quantitative PCR Assay for Human Infection by Anaplasma phagocytophilum and Ehrlichia chaffeensis. Trop Med Infect Dis 2018; 3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shakir SM, Mansfield CR, Hays ED, et al. Evaluation of a Novel High-Definition PCR Multiplex Assay for Simultaneous Detection of Tick-Borne Pathogens in Human Clinical Specimens. J Clin Microbiol 2020; 58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. MMWR Recomm Rep 2016; 65:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakken JS, Dumler JS. Ehrlichiosis and anaplasmosis. Infect Med 2004; 21:433.
          </a>
         </li>
         <li class="breakAll">
          United States Centers for Disease Control. Ehrlichiosis and Anaplasmosis 2008 Case Definition. https://ndc.services.cdc.gov/case-definitions/ehrlichiosis-and-anaplasmosis-2008/ (Accessed on February 21, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brouqui P, Bacellar F, Baranton G, et al. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin Microbiol Infect 2004; 10:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpenter CF, Gandhi TK, Kong LK, et al. The incidence of ehrlichial and rickettsial infection in patients with unexplained fever and recent history of tick bite in central North Carolina. J Infect Dis 1999; 180:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comer JA, Nicholson WL, Olson JG, Childs JE. Serologic testing for human granulocytic ehrlichiosis at a national referral center. J Clin Microbiol 1999; 37:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakken JS, Haller I, Riddell D, et al. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis 2002; 34:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paddock CD, Childs JE. Ehrlichia chaffeensis: a prototypical emerging pathogen. Clin Microbiol Rev 2003; 16:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton KS, Standaert SM, Kinney MC. Characteristic peripheral blood findings in human ehrlichiosis. Mod Pathol 2004; 17:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dawson JE, Paddock CD, Warner CK, et al. Tissue diagnosis of Ehrlichia chaffeensis in patients with fatal ehrlichiosis by use of immunohistochemistry, in situ hybridization, and polymerase chain reaction. Am J Trop Med Hyg 2001; 65:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumler JS, Dawson JE, Walker DH. Human ehrlichiosis: hematopathology and immunohistologic detection of Ehrlichia chaffeensis. Hum Pathol 1993; 24:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marty AM, Dumler JS, Imes G, et al. Ehrlichiosis mimicking thrombotic thrombocytopenic purpura. Case report and pathological correlation. Hum Pathol 1995; 26:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurin M, Bakken JS, Dumler JS. Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States. Antimicrob Agents Chemother 2003; 47:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buitrago MI, Ijdo JW, Rinaudo P, et al. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin Infect Dis 1998; 27:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abusaada K, Ajmal S, Hughes L. Successful Treatment of Human Monocytic Ehrlichiosis with Rifampin. Cureus 2016; 8:e444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamburg BJ, Storch GA, Micek ST, Kollef MH. The importance of early treatment with doxycycline in human ehrlichiosis. Medicine (Baltimore) 2008; 87:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakken JS, Dumler JS, Chen SM, et al. Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging? JAMA 1994; 272:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumler JS, Sutker WL, Walker DH. Persistent infection with Ehrlichia chaffeensis. Clin Infect Dis 1993; 17:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wormser GP, Filozov A, Telford SR 3rd, et al. Dissociation between inhibition and killing by levofloxacin in human granulocytic anaplasmosis. Vector Borne Zoonotic Dis 2006; 6:388.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Ehrlichia, anaplasma, and related infections. In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Ithaca, IL 2018. p.323.
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Tetracyclines. In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.905.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krause PJ, Corrow CL, Bakken JS. Successful treatment of human granulocytic ehrlichiosis in children using rifampin. Pediatrics 2003; 112:e252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith Sehdev AE, Sehdev PS, Jacobs R, Dumler JS. Human monocytic ehrlichiosis presenting as acute appendicitis during pregnancy. Clin Infect Dis 2002; 35:e99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vennila V, Madhu V, Rajesh R, et al. Tetracycline-induced discoloration of deciduous teeth: case series. J Int Oral Health 2014; 6:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohlan SQ, Bevelander G, Tiamsic T. Growth Inhibition of Prematures Receiving Tetracycline. Am J Dis Child 1963; 105:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf 2016; 15:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol 2009; 23:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein MB, Nelson CM, Goodman JL. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Antimicrob Agents Chemother 1997; 41:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little SE, Barrett AW, Nagamori Y, et al. Ticks from cats in the United States: Patterns of infestation and infection with pathogens. Vet Parasitol 2018; 257:15.
          </a>
         </li>
         <li class="breakAll">
          United States Centers for Disease Control. Preventing ticks on your pets. https://www.cdc.gov/ticks/avoid/on_pets.html (Accessed on August 20, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           des Vignes F, Piesman J, Heffernan R, et al. Effect of tick removal on transmission of Borrelia burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs. J Infect Dis 2001; 183:773.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7907 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3029590" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Human infection with Ehrlichia canis, a leukocytic rickettsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8195363" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10403852" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21812671" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21812671" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28699575" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Proposal to reclassify Ehrlichia muris as Ehrlichia muris subsp. muris subsp. nov. and description of Ehrlichia muris subsp. eauclairensis subsp. nov., a newly recognized tick-borne pathogen of humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11760958" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22647710" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Summary of notifiable diseases--United States, 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10341193" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : First case of human ehrlichiosis in Mexico.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18325283" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Ehrlichia chaffeensis in child, Venezuela.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19819631" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Natural history of Ehrlichia chaffeensis: vertebrate hosts and tick vectors from the United States and evidence for endemic transmission in other countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19779398" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Anaplasmosis and ehrlichiosis - Maine, 2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26621561" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Increasing Incidence of Ehrlichiosis in the United States: A Summary of National Surveillance of Ehrlichia chaffeensis and Ehrlichia ewingii Infections in the United States, 2008-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7616991" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Ehrlichiosis in a golf-oriented retirement community.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28518034" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Relative Risk for Ehrlichiosis and Lyme Disease in an Area Where Vectors for Both Are Sympatric, New Jersey, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25870428" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Human granulocytic anaplasmosis in the United States from 2008 to 2012: a summary of national surveillance data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25999228" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Human granulocytic anaplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25999228" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Human granulocytic anaplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10987720" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16485466" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Human granulocytic anaplasmosis and Anaplasma phagocytophilum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19836890" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Factors contributing to emergence of Ehrlichia and Anaplasma spp. as human pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15171823" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Multicentric study of seroprevalence of Borrelia burgdorferi and Anaplasma phagocytophila in high-risk groups in regions of central and southern Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30353471" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Diagnosis and molecular characteristics of human infections caused by Anaplasma phagocytophilum in South Korea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15146982" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Human granulocytic ehrlichiosis in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12519349" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Human granulocytic ehrlichiosis in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568857" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26402378" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Human Infection with Ehrlichia muris-like Pathogen, United States, 2007-2013(1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9203428" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9196173" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Isolation of Ehrlichia chaffeensis from wild white-tailed deer (Odocoileus virginianus) confirms their role as natural reservoir hosts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10998377" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Naturally occurring Ehrlichia chaffeensis infection in coyotes from Oklahoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11247714" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Ticks and tickborne bacterial diseases in humans: an emerging infectious threat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10618139" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Natural infection of domestic goats with Ehrlichia chaffeensis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18755383" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Human granulocytic anaplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431531" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Two cases of transfusion-transmitted Anaplasma phagocytophilum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22563784" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Transfusion-transmitted anaplasmosis from leukoreduced red blood cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23511303" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A confirmed Ehrlichia ewingii infection likely acquired through platelet transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30016241" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Death from Transfusion-Transmitted Anaplasmosis, New York, USA, 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24330198" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Severe life-threatening Ehrlichia chaffeensis infections transmitted through solid organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34670661" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Ehrlichiosis and Anaplasmosis among Transfusion and Transplant Recipients in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34329411" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Donor-derived Ehrlichiosis: 2 Clusters Following Solid Organ Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9691104" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Perinatal transmission of the agent of human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8816164" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Exposure to deer blood may be a cause of human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8967671" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Human granulocytic ehrlichiosis: a case series from a medical center in New York State.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8147545" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Human ehrlichiosis in adults after tick exposure. Diagnosis using polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8147546" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Human ehrlichiosis in the United States, 1985 to 1990.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8604172" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Clinical and laboratory characteristics of human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8842270" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Central nervous system manifestations of human ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10391189" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Ehrlichial meningitis with cerebrospinal fluid morulae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795080" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Ehrlichiosis--a cause of prolonged fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8603945" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Human granulocytic ehrlichiosis in Wisconsin and Minnesota: a frequent infection with the potential for persistence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22354925" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Fatal ehrlichial myocarditis in a healthy adolescent: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17529862" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Human monocytic ehrlichiosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29050793" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Anaplasmosis in pediatric patients: Case report and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17682993" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Human granulocytic anaplasmosis during pregnancy: case series and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18509484" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Human granulocytic ehrlichiosis complicating early pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12578161" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Treatment of human granulocytic ehrlichiosis during pregnancy and risk of perinatal transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33417672" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20052776" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Severe ehrlichia infection in pediatric oncology and stem cell transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7619983" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Ehrlichial diseases of humans: emerging tick-borne infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11247709" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8838212" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Human ehrlichiosis causing left ventricular dilatation and dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8531996" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Direct cultivation of the causative agent of human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19017912" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Nosocomial transmission of human granulocytic anaplasmosis in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16481544" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Anaplasma and Ehrlichia infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28584460" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hemophagocytic Lymphohistiocytosis Associated with Anaplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26227842" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Ehrlichia-Induced Hemophagocytic Lymphohistiocytosis: A Case Series and Review of Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32706439" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Incidence and treatment of hemophagocytic lymphohistiocytosis in hospitalized children with Ehrlichia infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30913447" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Human ehrlichiosis at a tertiary-care academic medical center: Clinical associations and outcomes of transplant patients and patients with hemophagocytic lymphohistiocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9827293" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Demyelinating polyneuropathy associated with human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8780084" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Brachial plexopathy associated with human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9213773" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12804168" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Epidemiology and impact of coinfections acquired from Ixodes ticks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9621205" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Dual infection with Ehrlichia chaffeensis and a spotted fever group rickettsia: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33201233" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Assessment of Risk Factors and Outcomes of Severe Ehrlichiosis Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34517150" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Ehrlichiosis and anaplasmosis subcommittee report to the Tick-borne Disease Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11927032" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Severe Ehrlichia chaffeensis infection in a lung transplant recipient: a review of ehrlichiosis in the immunocompromised patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11435982" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Human monocytic ehrlichiosis: an emerging pathogen in transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9735084" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Reinfection with the agent of human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9735084" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Reinfection with the agent of human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16263231" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A real-time combined polymerase chain reaction assay for the rapid detection and differentiation of Anaplasma phagocytophilum, Ehrlichia chaffeensis, and Ehrlichia ewingii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30274412" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Development and Clinical Validation of a Multiplex Real-Time Quantitative PCR Assay for Human Infection by Anaplasma phagocytophilum and Ehrlichia chaffeensis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31852765" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Evaluation of a Novel High-Definition PCR Multiplex Assay for Simultaneous Detection of Tick-Borne Pathogens in Human Clinical Specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27172113" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Ehrlichiosis and anaplasmosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Ehrlichiosis and anaplasmosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16572105" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15606643" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Guidelines for the diagnosis of tick-borne bacterial diseases in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10438390" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : The incidence of ehrlichial and rickettsial infection in patients with unexplained fever and recent history of tick bite in central North Carolina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9986812" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Serologic testing for human granulocytic ehrlichiosis at a national referral center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11731941" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The serological response of patients infected with the agent of human granulocytic ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12525424" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Ehrlichia chaffeensis: a prototypical emerging pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14976527" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Characteristic peripheral blood findings in human ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11716122" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Tissue diagnosis of Ehrlichia chaffeensis in patients with fatal ehrlichiosis by use of immunohistochemistry, in situ hybridization, and polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8491479" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Human ehrlichiosis: hematopathology and immunohistologic detection of Ehrlichia chaffeensis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7635455" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Ehrlichiosis mimicking thrombotic thrombocytopenic purpura. Case report and pathological correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12499227" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9675481" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26918212" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Successful Treatment of Human Monocytic Ehrlichiosis with Rifampin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344803" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : The importance of early treatment with doxycycline in human ehrlichiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8022040" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8286638" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Persistent infection with Ehrlichia chaffeensis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17187574" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Dissociation between inhibition and killing by levofloxacin in human granulocytic anaplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17187574" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Dissociation between inhibition and killing by levofloxacin in human granulocytic anaplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17187574" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Dissociation between inhibition and killing by levofloxacin in human granulocytic anaplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12949322" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Successful treatment of human granulocytic ehrlichiosis in children using rifampin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12384854" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Human monocytic ehrlichiosis presenting as acute appendicitis during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25083046" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Tetracycline-induced discoloration of deciduous teeth: case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Growth Inhibition of Prematures Receiving Tetracycline
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26680308" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19228311" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8980758" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29907187" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Ticks from cats in the United States: Patterns of infestation and infection with pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29907187" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Ticks from cats in the United States: Patterns of infestation and infection with pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11181154" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Effect of tick removal on transmission of Borrelia burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
